COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Metformin in Pregnancy in Women With Polycystic Ovary Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01594697
Recruitment Status : Completed
First Posted : May 9, 2012
Last Update Posted : May 11, 2012
Information provided by (Responsible Party):
Maurizio Guido, Catholic University of the Sacred Heart

Brief Summary:
The study provide a detailed longitudinal evaluation of the gluco-insulinemic assessment of pregnant PCOS women under metformin treatment. 47 non diabetic Polycystic Ovary Syndrome (PCOS) women became pregnant during metformin treatment and continued taking the drug during gestation. An oral glucose tolerance test and euglycaemic hyperinsulinaemic clamp were performed at each trimester of gestation.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Drug: Metformin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: metformin Drug: Metformin

Primary Outcome Measures :
  1. incidence of gestational diabetes

Secondary Outcome Measures :
  1. rate of spontaneous abortion
  2. number of hypertensive disorders
  3. number of live births
  4. number of newborns with macrosomia
  5. incidence of delivery by caesarian section

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • age 18-40 yr,
  • metformin treatment for at least 3 months before entering the pregnancy,
  • gestational age between 5 and 12 wk

Exclusion Criteria:

  • diabetes mellitus
  • significant liver or renal impairment
  • neoplasms and other endocrine diseases
  • the use of drugs other than metformin able to interfere with glucose and insulin metabolism.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01594697

Layout table for location information
Catholic University of Sacred Heart
Rome, Italy, 00168
Sponsors and Collaborators
Catholic University of the Sacred Heart
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maurizio Guido, Principal Investigator, Catholic University of the Sacred Heart Identifier: NCT01594697    
Other Study ID Numbers: 000082011
First Posted: May 9, 2012    Key Record Dates
Last Update Posted: May 11, 2012
Last Verified: May 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs